These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3518270)

  • 1. [Further study of the prevention of streptococcal infections in experiments on monkeys].
    Keller V; Dzhikidze EK; Voskanian NA; Kiunemund O; Knol' G
    Vestn Akad Med Nauk SSSR; 1986; (3):66-8. PubMed ID: 3518270
    [No Abstract]   [Full Text] [Related]  

  • 2. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 3. [Primary prevention of rheumatism: the status and outlook (vaccine)].
    Rotta Y
    Ter Arkh; 1985; 57(11):97-100. PubMed ID: 3909476
    [No Abstract]   [Full Text] [Related]  

  • 4. Vaccination of pony foals with M-like protein of Streptococcus equi.
    Srivastava SK; Barnum DA
    Am J Vet Res; 1983 Jan; 44(1):41-5. PubMed ID: 6824223
    [No Abstract]   [Full Text] [Related]  

  • 5. Group A streptococcus vaccine may be ready for phase I clinical trials in late 1989.
    Raymond CA
    JAMA; 1988 Nov; 260(19):2778. PubMed ID: 3054182
    [No Abstract]   [Full Text] [Related]  

  • 6. Epidemiologic profile of streptococcal infections in collectivities of children followed over a sixteen year period.
    Măgureanu E; Dobrescu A; Horhogea G; Ulmeanu V; Grigoriu T; Debeleac L; Ionescu M; Ionescu E; Zolotovschi JC
    J Hyg Epidemiol Microbiol Immunol; 1982; 26(4):375-84. PubMed ID: 6761392
    [No Abstract]   [Full Text] [Related]  

  • 7. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunity to group a streptococcal M proteins: forging a single-edged sword.
    Madoff LC
    Clin Infect Dis; 2005 Oct; 41(8):1123-4. PubMed ID: 16163630
    [No Abstract]   [Full Text] [Related]  

  • 9. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcal vaccines revisited.
    Stollerman GH
    J Lab Clin Med; 1978 Jun; 91(6):872-80. PubMed ID: 77303
    [No Abstract]   [Full Text] [Related]  

  • 12. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions.
    Fischetti VA; Bessen DE; Schneewind O; Hruby DE
    Adv Exp Med Biol; 1991; 303():159-67. PubMed ID: 1805563
    [No Abstract]   [Full Text] [Related]  

  • 13. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
    Relf W; Hayman W; Russell-Jones G; Good M
    Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
    [No Abstract]   [Full Text] [Related]  

  • 14. Group A streptococcal adhesion. All of the theories are correct.
    Hasty DL; Courtney HS
    Adv Exp Med Biol; 1996; 408():81-94. PubMed ID: 8895780
    [No Abstract]   [Full Text] [Related]  

  • 15. Changing epidemiology of acute rheumatic fever in the United States.
    Lee GM; Wessels MR
    Clin Infect Dis; 2006 Feb; 42(4):448-50. PubMed ID: 16421786
    [No Abstract]   [Full Text] [Related]  

  • 16. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
    Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
    J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Streptococcal M protein.
    Fischetti VA
    Sci Am; 1991 Jun; 264(6):58-65. PubMed ID: 1857955
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune response to superoxide dismutase in group A streptococcal infection.
    McMillan DJ; Davies MR; Good MF; Sriprakash KS
    FEMS Immunol Med Microbiol; 2004 Apr; 40(3):249-56. PubMed ID: 15039102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Curative and prophylactic immunomodulation by vaccination in mucocutaneous streptococcal infections].
    Topciu V; Teodorescu M; Sedan D
    Bacteriol Virusol Parazitol Epidemiol; 1996; 41(1-2):71-3. PubMed ID: 8963122
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.